India's first indigenous mRNA vaccine likely to be available soon

The Subject Expert Committee (SEC) has recommended granting the Emergency Use Authorisation (EUA) to the country's first mRNA-based Covid-19 vaccine in a meeting held on Friday

Gennova
Gennova's vaccine has an edge over its international peers as it does not require sub-zero temperatures like Pfizer-BioNTech and Moderna's vaccines
Sohini Das
2 min read Last Updated : Jun 28 2022 | 10:47 AM IST
Soon India may have its first indigenous mRNA vaccine that is stable at 2-8 degrees Celsius as the expert panel advising the Central Drugs Standards Control Organisation (CDSCO) has green-signalled Gennova Biopharma's mRNA vaccine candidate for Covid19.

The Subject Expert Committee (SEC) has recommended granting the Emergency Use Authorisation (EUA) to the country's first mRNA-based Covid-19 vaccine in a meeting held on Friday, according to reports.

Now, the Drugs Controller General of India (DCGI) will take a final call on granting the final approval.

The SEC has reviewed data from the trials done on 4000 volunteers. The CDSCO had raised some queries after Gennova had submitted interim data from the trials in April. The company submitted the additional data eventually. In June, the company further approached CDSCO seeking approval.

Gennova's vaccine has an edge over its international peers as it does not require sub-zero temperatures like Pfizer-BioNTech and Moderna's vaccines.

NK Arora, head of Covid-19 working group, NTAGI, had earlier told Business Standard that they would consider the indigenous mRNA vaccine for inclusion in India's ongoing national program for Covid19 vaccination.

The vaccine, however, is embroiled in controversies. US firm HDT Bio Corp has filed a lawsuit in a Seattle federal court against Gennova's parent company Emcure Pharmaceuticals. HDT has accused Emcure of 'stealing' and misappropriation of HDT's billion-dollar trade secrets and sought $950 million in damages. The US firm has alleged that Emcure' willfully and maliciously violated the Defend Trade Secrets Act and Washington's laws against trade secret theft.

Legal experts feel that the reliefs requested by HDT are primarily monetary in nature and not aimed at inducing any form of injunctions.

The lawsuit in a Seattle court by a US-based start-up may not immediately impact the launch of Pune-based Gennova Biopharmaceuticals' mRNA vaccine HGCO19; once the vaccine receives the Indian regulator's nod, feel legal experts. The long-term prospects of the vaccine may depend on how the case progresses.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus Vaccinepharmaceutical firmsHealth Ministrypublic healthVaccine

Next Story